RESEARCH ARTICLE

Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy

Carmine Rossi1, Janet Raboud2,3, Sharon Walmsley3, Curtis Cooper4, Tony Antoniou5, Ann N. Burchell5, Mark Hul6,7, Jason Chia8, Robert S. Hogg6,8, Erica E.M. Moodie9, Marina B. Klein1,10* and the Canadian Observational Cohort (CANOC) Collaboration

Abstract

Background: Combination antiretroviral therapy (cART) has reduced mortality from AIDS-related illnesses and chronic comorbidities have become prevalent among HIV-infected patients. We examined the association between hepatitis C virus (HCV) co-infection and chronic kidney disease (CKD) among patients initiating modern antiretroviral therapy.

Methods: Data were obtained from the Canadian HIV Observational Cohort for individuals initiating cART from 2000 to 2012. Incident CKD was defined as two consecutive serum creatinine-based estimated glomerular filtration (eGFR) measurements <60 mL/min/1.73m^2 obtained ≥3 months apart. CKD incidence rates after cART initiation were compared between HCV co-infected and HIV mono-infected patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox regression.

Results: We included 2595 HIV-infected patients with eGFR >60 mL/min/1.73m^2 at cART initiation, of which 19% were HCV co-infected. One hundred and fifty patients developed CKD during 10,903 person-years of follow-up (PYFU). The CKD incidence rate was higher among co-infected than HIV mono-infected patients (26.0 per 1000 PYFU vs. 10.7 per 1000 PYFU). After adjusting for demographics, virologic parameters and traditional CKD risk factors, HCV co-infection was associated with a significantly shorter time to incident CKD (HR 1.97; 95% CI: 1.33, 2.90). Additional factors associated with incident CKD were female sex, increasing age after 40 years, lower baseline eGFR below 100 mL/min/1.73m^2, increasing HIV viral load and cumulative exposure to tenofovir and lopinavir.

Conclusions: HCV co-infection was associated with an increased risk of incident CKD among HIV-infected patients initiating cART. HCV-HIV co-infected patients should be monitored for kidney disease and may benefit from available HCV treatments.

Keywords: Antiretroviral therapy, Chronic kidney disease, Co-infection, Glomerular filtration, Hepatitis C, HIV

* Correspondence: marina.klein@mcgill.ca
1Research Institute of the McGill University Health Centre, Montréal, Canada
2Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, 1001 Decarie Boulevard, D02.4110, Montréal H4A 3J1, Canada
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Combination antiretroviral therapy (cART) has been associated with both a substantial reduction in AIDS and greater life expectancies in both low and high-income HIV settings [1–3]. With increasing life expectancies, morbidity and mortality from non-AIDS and ageing-related co-morbidities account for a larger proportion of the HIV disease burden [4]. Co-infection with chronic hepatitis C virus (HCV) is common among HIV-infected patients and is associated with many of the extrahepatic, non-AIDS and ageing-related co-morbidities observed in this population [5]. These co-morbidities include cardiovascular, metabolic, renal, and neurological illnesses, which have been attributed to chronic HCV infection in both the general and HIV-infected populations [6–8]. Indeed, the diagnoses of these extrahepatic illnesses have increased among hospitalized patients with HCV and account for a greater proportion of health service utilization among co-infected individuals [9, 10].

Chronic kidney disease (CKD) is an important comorbidity in HIV-infected persons [11]. If left unmanaged, HIV-infected patients with CKD are at greater risk of serious cardiovascular complications and premature mortality [12–14]. The etiology of CKD in HIV-infected patients is complex and has been related to both traditional, non-viral kidney impairment risk factors, such as hypertension, diabetes, dyslipidemia, and the use of non-steroidal anti-inflammatory drugs (NSAIDs), whose prevalence have all increased in the modern cART era, as well as emerging HIV-related risk factors, such as long-term use of potentially nephrotoxic antiviral agents, incomplete immune recovery, and ongoing substance abuse [15–17]. Chronic HCV has been both directly and indirectly implicated in the development of CKD. Directly, HCV has been associated with the development of glomerulonephritis, via increased autoantibody IgM production with rheumatoid factor activity, leading to mixed cryoglobulinemia and deposition into glomerular capillary and tubules [18, 19]. Indirectly, HCV has been associated with an increased risk of insulin resistance and atherosclerosis, which are important CKD risk factors [20].

Given the complex interplay between viral and non-viral risk factors, the impact that chronic HCV may have on CKD in the modern cART era is unclear. A meta-analysis of 27 studies in HIV-infected individuals enrolled between 1989 and 2006 showed that HCV infection was associated with an increased risk of CKD. However, there was both statistical heterogeneity and variation in measured outcomes (i.e. CKD measured by proteinuria, hospitalization, incidence of HIV-associated nephropathy (HIVAN), or increased creatinine concentration), as well as no adjustment for confounding [21]. Studies included a combination of treatment-naïve and experienced patients, including treatment with indinavir, and therefore may no longer be representative of the HIV-infected population currently in clinical care. The objective of this study was to determine if HCV co-infection is associated with an increased risk of incident CKD in a cohort of HIV-infected Canadians initiating modern antiretroviral therapy.

Methods
Study population
Data were analyzed from the Canadian Observational Cohort (CANOC) [22]. This retrospective HIV cohort study is a collaboration of eight separate population and clinic-based cohorts from Canada’s largest provinces. Briefly, treatment-naïve HIV-infected patients who have initiated cART since January 1st, 2000, are eligible for inclusion. The cohort is broadly representative of the HIV population accessing treatment and comprises approximately half of all individuals who have initiated cART in Canada since 2000 [22]. Every second year, each participating cohort electronically submits a pre-defined series of demographic, clinical, and HIV treatment variables for their patients to the Data Coordinating Site at the British Columbia Centre for Excellence in HIV/AIDS Research. As of December 31st, 2012, 8980 cART initiators have been included in CANOC. All participating cohorts have received approval from their institutional ethics boards to contribute anonymous patient data to CANOC.

Study design and inclusion criteria
A longitudinal cohort design was employed to examine the association between HCV co-infection and incident CKD. We defined baseline as the date of cART initiation and we included all individuals who (1) had at least one serum creatinine (SCr) measurement within 30 days prior to starting cART or up to 7 days after, (2) had at least two follow-up SCr measurements, at least 90 days apart, and (3) did not have a baseline estimated glomerular filtration rate (eGFR) measurement <60 mL/min/1.73 m² (see below).

Chronic kidney disease
We calculated eGFR using the 2009 SCr-based CKD-EPI equation [23]. This equation has been validated in HIV-infected populations [24]. Confirmed incident CKD was defined as two consecutive eGFR measurements <60 mL/min/1.73 m², obtained at least 90 days apart. The CKD event date was on the second of the two required eGFR measurements.

Study covariates
HCV exposure was ascertained by a positive HCV antibody test, qualitative or quantitative HCV RNA analysis,
HCV exposure was considered time-fixed irrespective of when the diagnosis or testing results were reported, as HCV infection precedes cART initiation in the vast majority of HIV-infected Canadians [25]. African/Caribbean ethnicity and injection drug use (IDU) as an HIV risk factor were obtained by patient self-report at baseline from patients in the Ontario HIV Treatment Network Cohort Study, from enrolment forms into the Drug Treatment Program in British Columbia, or from review of medical charts for other cohorts. Diabetes was defined by either clinical diagnoses or random serum glucose \( \geq 11.1 \text{ mmol/L} \). Hypertension was also defined by either clinical diagnoses or systolic blood pressure \( \geq 140 \text{ mmHg} \) or diastolic blood pressure \( \geq 90 \text{ mmHg} \) [26]. Liver fibrosis was measured using the aspartate aminotransferase-to-platelet ratio index (APRI) and values \( \geq 1.5 \) were indicative of moderate fibrosis [27]. AIDS-defining events were defined based on the 1993 Centers for Disease Control and Prevention classification [28].

Statistical analyses

Eligible patients were followed from baseline (i.e. cART initiation) until the earliest of (1) incident CKD, (2) death, (3) loss-to-follow-up, or (4) study end date of December 31st, 2012. Person-time for individuals without CKD was censored at the date of the last eGFR measurement or date of death. Cumulative incidence curves were created to explore the association between HCV and CKD-free survival [29]. Univariable and multivariable Cox proportional hazards (PH) models were fit to examine the association between HCV co-infection and CKD. The multivariable model was adjusted for baseline age, sex, African/Caribbean ethnicity, eGFR, and year of cART initiation and time-updated measurements of CD4\(^+\) cell count, HIV viral load, liver fibrosis, and tenofovir, atazanavir, and lopinavir use. A second model additionally adjusted for time-updated diabetes and hypertension. Covariates were selected a priori based on their plausibility as confounders. As there was evidence of non-linearity between age and baseline eGFR with CKD, we modeled these covariates with linear splines with a single age knot at 40 years and a single baseline eGFR knot at 100 mL/min/1.73 m\(^2\) [30]. Chronic comorbid conditions of liver fibrosis, diabetes and hypertension were modeled as cumulative binary exposures and the antiretroviral agents were modeled as cumulative use. We explored interaction between HCV co-infection and IDU as an HIV risk factor, as previous research has shown poorer clinical outcomes for this group [31]. Missing covariate data for HCV co-infection, African/Caribbean ethnicity, liver fibrosis, diabetes and hypertension was handled using fully conditional specification multiple imputation (MI) [32]. The imputation model included all covariates in the multivariable model, an indicator for CKD, and a measure of the cumulative baseline hazard using the Nelson-Aalen estimator [33]. We created 10 imputed data sets and combined regression results using Rubin’s rules [32].

We also performed several sensitivity analyses. First, given there were a large proportion of patients without a baseline eGFR that were excluded from the analysis, we used inverse-probability weighting to account for the fact that certain patients were under-represented in our analytical cohort [34]. Second, because there is a strong relationship between increasing age and declining kidney function, we considered using age as the time scale in the primary Cox PH model. Third, we considered reclassifying exposed co-infected person-time based on the date of first positive HCV serologic or molecular test, rather than assume patients were initially co-infected [35]. Lastly, given the large number of missing data on hypertension, we examined the sensitivity of the missing at random MI assumption [36]. STATA version 13.1 (College Station, TX) and SAS version 9.4 (Cary, NC) were used for the analyses.

Results

Of the 8980 patients who initiated cART between January 1st, 2000, and December 31st, 2012, 2595 (29%) were eligible for inclusion into our study (Fig. 1). Most patients were excluded (64%) because they did not have a baseline SCr measurement. Excluded individuals were more likely to be female, white, HCV co-infected, report IDU as an HIV risk factor, and used tenofovir-based initial cART regimen (see Additional file 1: Table S1).

Baseline patient characteristics, overall and stratified by HCV co-infection, are presented in Table 1. Most of the study patients were male (85%) and the median age
was 40 years (interquartile range [IQR]: 33, 46). Among the 2595 included patients, 2462 (95%) were screened for HCV. Of these, 484 (20%) were co-infected, with 107 (22%) confirmed as having chronic HCV with molecular HCV RNA testing. Compared to HIV mono-infected, co-infected patients were older, less likely to be male or of African/Caribbean ethnicity, more likely to have a history of IDU and have liver fibrosis, less likely to be on a tenofovir-based initial cART regimen and had lower baseline CD4+ cell counts.

Of the 2595 patients in the study, 150 (6%) developed incident CKD over a total of 10,903 person-years of follow-up (PYFU). The overall crude incidence rate was 13.8 per 1000 PYFU (95% confidence interval (CI): 11.7, 16.1). The median follow-up time was 3.5 years (IQR: 1.7, 6.1). Of the 2445 patients who were censored without developing CKD, 141 died (6%), 576 were lost-to-follow-up (23%), and the remaining 1728 were administratively censored (71%).

Incidence rates for CKD stratified by demographic and clinical characteristics are presented in Table 2. Crude rates were higher in females, older age groups, non-African/Caribbeans, individuals with IDU as an HIV risk factor, and those with a lower baseline eGFR. CKD incidence did not increase with calendar time. The incidence of CKD among co-infected patients was substantially higher than the rate among HIV mono-infected patients; 26.0 per 1000 PYFU (95% CI: 20.0, 33.8) and 10.7 per 1000 PYFU (95% CI: 8.7, 13.2), respectively. The median follow-up time was similar in both groups. The incidence rate of CKD among those with an unknown HCV status was similar to the HIV mono-infected group (11.1 per 1000 PYFU; 95% CI: 4.6, 26.7). Figure 2 depicts the cumulative incidence function for CKD by HCV co-infection status. Among co-infected, the five-year cumulative risk of CKD after initiating cART was 11%, compared to 5% among HIV mono-infected patients.

In univariable analysis, HCV co-infection was significantly associated with CKD (hazard ratio (HR) 2.49; 95% CI: 1.79, 3.48) and remained so after adjustment (HR 1.97; 95% CI: 1.33, 2.90). Female sex (HR 2.16; 95% CI: 1.42, 3.28), increasing age after 40 years (HR 1.51 per 5 year increase; 95% CI: 1.35, 1.67), increasing baseline eGFR up to 100 mL/min/1.73 m\(^2\) (HR 0.60 per 5 mL/min/1.73 m\(^2\) increase; 95% CI:

### Table 1: Baseline study characteristics, overall and stratified by hepatitis C virus co-infection

|                          | Overall (n = 2595) | HCV positive (n = 484) | HCV negative (n = 1978) | Unknown (n = 133) |
|--------------------------|--------------------|------------------------|------------------------|-------------------|
| Median age (IQR), years  | 40 (33, 46)        | 41 (35, 47)            | 39 (33, 46)            | 41 (36, 49)       |
| Male sex                 | 2195 (85%)         | 394 (81%)              | 1690 (85%)             | 111 (83%)         |
| African/Caribbean ethnicity | 368 (24%)           | 17 (5%)                | 344 (29%)              | 17 (27%)          |
| Median eGFR (IQR), mL/min/1.73 m\(^2\) | 105 (92, 116) | 103 (91, 114) | 105 (92, 117) | 106 (96, 115) |
| Injection drug use as HIV risk factor b | 389 (18%)            | 302 (69%)              | 83 (5%)                | 4 (4%)            |
| Median CD4+ cell count (IQR), cells/μL | 210 (102, 318) | 190 (80, 290) | 220 (110, 323) | 200 (100, 319) |
| Median HIV viral load (IQR), log\(_{10}\) copies/mL | 4.9 (4.4, 5.2) | 4.9 (4.4, 5.1) | 4.9 (4.4, 5.2) | 4.9 (4.4, 5.2) |
| Previous AIDS-defining event c | 450 (19%)        | 99 (22%)               | 331 (19%)              | 20 (18%)          |
| Tenofovir use            | 1410 (54%)         | 227 (47%)              | 1111 (56%)             | 72 (54%)          |
| Atazanavir use           | 666 (26%)          | 144 (30%)              | 494 (25%)              | 28 (21%)          |
| Lopinavir use            | 471 (18%)          | 99 (20%)               | 347 (18%)              | 25 (19%)          |
| Median year of cART initiation (IQR) | 2007 (2004, 2009) | 2006 (2003, 2009) | 2008 (2004, 2009) | 2008 (2004, 2010) |
| Liver fibrosis (APRI ≥1.5) d | 145 (7%)            | 69 (17%)               | 71 (5%)                | 5 (6%)            |
| Diabetes e               | 119 (5%)           | 26 (6%)                | 89 (5%)                | 4 (3%)            |
| Hypertension f           | 74 (12%)           | 13 (15%)               | 59 (12%)               | 2 (8%)            |
| Cohort province          |                    |                       |                        |                   |
| British Columbia         | 1103 (43%)         | 307 (63%)              | 738 (37%)              | 58 (44%)          |
| Ontario                  | 838 (32%)          | 110 (23%)              | 694 (35%)              | 34 (26%)          |
| Québec                   | 654 (25%)          | 67 (14%)               | 546 (28%)              | 41 (31%)          |

### Notes:

- APRI = aspartate aminotransferase to platelet ratio index, cART = combination antiretroviral therapy, IQR = interquartile range, eGFR = estimated glomerular filtration rate, HCV = hepatitis C virus.
- a 1045 participants (40%) are missing data on African/Caribbean ethnicity; 138 among HCV Positive, 838 among HCV Negative, and 69 among the Unknown.
- b 431 participants (17%) are missing data on injection drug use risk factor; 44 among HCV Positive, 344 among HCV Negative, and 43 among the Unknown.
- c 246 participants (9%) are missing previous AIDS event histories; 31 among HCV Positive, 197 among HCV Negative, and 18 among the Unknown.
- d 603 participants (23%) are missing data on liver fibrosis; 73 among HCV Positive, 484 among HCV Negative, and 46 among the Unknown.
- e 142 participants (5%) are missing data on diabetes; 13 among HCV Positive, 111 among HCV Negative, and 18 among the Unknown.
- f 1973 participants (76%) are missing data on hypertension; 395 among HCV Positive, 1470 among HCV Negative, and 108 among the Unknown.
HIV viral load (HR 1.20 per log10 increase; 95% CI: 1.01, 1.43) and cumulative exposure to lopinavir (HR 1.12 per additional year of use, 95% CI: 1.02, 1.22) were also associated with CKD in the multivariable model (Table 3). Liver fibrosis also demonstrated a trend towards greater risk of CKD (HR 1.50; 95% CI: 0.98, 2.30). In a secondary analysis, including hypertension and diabetes from the model did not appreciably change the results (HR 2.02; 95% CI: 1.36, 2.99), although tenofovir use was now associated with CKD (HR 1.12 per additional year of use, 95% CI: 1.00, 1.25). The effect of HCV co-infection did not differ between those who had IDU as a HIV risk factor and those who did not (p-value for interaction term, 0.94).

Results from all sensitivity analyses were quantitatively similar to the main findings. With an inverse-probability weighted sample to account for potential selection bias, the adjusted HR for HCV co-infection was similar (HR 2.14; 95% CI: 1.44, 3.20; see Additional file 1: Table S3). When we considered person-time prior to a patient’s first positive HCV antibody or molecular test to be unexposed, the adjusted effect estimate was slightly attenuated (HR 1.82; 95% CI: 1.22, 2.73). Estimates from our additional MI scenarios, where we assumed missing data patterns for hypertension depended on unobserved data, were robust to our missing data assumptions (see Additional file 1: Table S4).

**Discussion**

In this analysis of HIV-infected individuals initiating cART, we found that HCV co-infection was associated with a shorter time to incident CKD using a confirmed eGFR-based definition. This finding was independent of traditional CKD risk factors, which have become more prevalent in HIV-infected patients in the modern cART era [15]. Results were consistent for all sensitivity analyses using different estimation techniques. The adjusted effect size for HCV co-infection was relatively larger than other important CKD risk factors such as hypertension, diabetes, and exposure to nephrotoxic agents, such as tenofovir, atazanavir and lopinavir/ritonavir. These findings support the current guidelines for the diagnosis and management of CKD among HIV patients, which recommend annual monitoring of kidney function among those co-infected with HCV [37]. Identification of HIV patients at greatest risk of developing CKD will help targeted implementation of preventative and therapeutic strategies to slow renal function decline and determine which patients may benefit to switching newer cART regimens with safer renal profiles [38].

This is the first study to estimate the incidence of CKD among HIV-infected patients after initiating cART, which we estimated at 14 per 1000 PYFU. Previous studies have included a combination of treatment-naïve and experienced patients [39, 40], failed to use a confirmatory eGFR measurement [41, 42], or did not perform multivariable analyses [43]. Generally, results from our study were consistent with findings from other observational HIV

| Characteristic | Chronic kidney Disease events | Total Person-years | Incidence rate per 1000 Person-years (95% CI) |
|---------------|-------------------------------|-------------------|---------------------------------------------|
| Overall       | 150                           | 10,903.4          | 13.8 (11.7, 16.1)                           |
| Sex           |                               |                   |                                             |
| Male          | 115                           | 9130.4            | 12.6 (10.5, 15.1)                           |
| Female        | 35                            | 1773.0            | 19.7 (14.2, 27.5)                           |
| Ethnicity     |                               |                   |                                             |
| African/Caribbean | 15                  | 1806.6            | 8.3 (5.0, 13.7)                             |
| Non-African/Caribbean | 97              | 5742.7            | 16.9 (13.8, 20.6)                           |
| Unknown       | 38                            | 3354.0            | 11.3 (8.2, 15.6)                            |
| Hepatitis C Co-Infection |         |                   |                                             |
| Yes           | 56                            | 2156.0            | 26.0 (20.0, 33.8)                           |
| No            | 89                            | 8297.3            | 10.7 (8.7, 13.2)                            |
| Unknown       | 5                             | 450.2             | 11.1 (4.6, 26.7)                            |
| HIV Risk Factor |                             |                   |                                             |
| Injection drug use | 45                  | 1709.7            | 25.1 (18.8, 33.7)                           |
| Non-injection drug use | 89             | 7640.4            | 11.6 (9.5, 14.3)                            |
| Unknown       | 16                            | 1472.3            | 10.9 (6.7, 17.7)                            |
| Age at cART initiation, years |         |                   |                                             |
| 18–39         | 43                            | 5342.6            | 8.0 (6.0, 10.9)                             |
| 40–49         | 41                            | 3874.6            | 10.6 (7.8, 14.4)                            |
| 50–59         | 40                            | 1369.5            | 29.2 (21.4, 39.8)                           |
| ≥ 60          | 26                            | 316.7             | 82.1 (55.9, 120.6)                          |
| Baseline eGFR, mL/min/1.73m² |         |                   |                                             |
| > 110         | 25                            | 3906.9            | 6.4 (4.3, 9.5)                              |
| > 90 & ≤ 110  | 41                            | 4405.5            | 9.3 (6.9, 12.6)                             |
| ≤ 90          | 84                            | 2591.0            | 32.4 (26.2, 40.2)                           |
| Year of Follow-up |                 |                   |                                             |
| 2000–2003     | 14                            | 966.4             | 14.5 (8.6, 24.5)                            |
| 2004–2008     | 58                            | 4324.0            | 13.4 (10.4, 17.3)                           |
| 2009–2012     | 78                            | 5613.0            | 13.9 (11.1, 17.3)                           |

**Table 2** Crude incidence rates of chronic kidney disease, Canadian Observational Cohort 2000–2012

*cART* combination antiretroviral therapy, CI confidence interval, eGFR estimated glomerular filtration rate

0.52, 0.69), HIV viral load (HR 1.20 per log10 increase; 95% CI: 1.01, 1.43) and cumulative exposure to lopinavir (HR 1.12 per additional year of use, 95% CI: 1.02, 1.22) were also associated with CKD in the multivariable model (Table 3). Liver fibrosis also demonstrated a trend towards greater risk of CKD (HR 1.50; 95% CI: 0.98, 2.30). In a secondary analysis, including hypertension and diabetes from the model did not appreciably change the results (HR 2.02; 95% CI: 1.36, 2.99), although tenofovir use was now associated with CKD (HR 1.12 per additional year of use, 95% CI: 1.00, 1.25). The effect of HCV co-infection did not differ between those who had IDU as a HIV risk factor and those who did not (p-value for interaction term, 0.94).

Results from all sensitivity analyses were quantitatively similar to the main findings. With an inverse-probability weighted sample to account for potential selection bias, the adjusted HR for HCV co-infection was similar (HR 2.01; 95% CI: 1.34, 3.01; see Additional file 1: Table S2). When using age as the time scale, rather than time from cART initiation, the adjusted HR increased slightly (HR 2.14; 95% CI: 1.44, 3.20; see Additional file 1: Table S3). When we considered person-time prior to a patient's first positive HCV antibody or molecular test to be unexposed, the adjusted effect estimate was slightly attenuated (HR 1.82; 95% CI: 1.22, 2.73). Estimates from our additional MI scenarios, where we assumed missing data patterns for hypertension depended on unobserved data, were robust to our missing data assumptions (see Additional file 1: Table S4).

**Discussion**

In this analysis of HIV-infected individuals initiating cART, we found that HCV co-infection was associated with a shorter time to incident CKD using a confirmed eGFR-based definition. This finding was independent of traditional CKD risk factors, which have become more prevalent in HIV-infected patients in the modern cART era [15]. Results were consistent for all sensitivity analyses using different estimation techniques. The adjusted effect size for HCV co-infection was relatively larger than other important CKD risk factors such as hypertension, diabetes, and exposure to nephrotoxic agents, such as tenofovir, atazanavir and lopinavir/ritonavir. These findings support the current guidelines for the diagnosis and management of CKD among HIV patients, which recommend annual monitoring of kidney function among those co-infected with HCV [37]. Identification of HIV patients at greatest risk of developing CKD will help targeted implementation of preventative and therapeutic strategies to slow renal function decline and determine which patients may benefit to switching newer cART regimens with safer renal profiles [38].

This is the first study to estimate the incidence of CKD among HIV-infected patients after initiating cART, which we estimated at 14 per 1000 PYFU. Previous studies have included a combination of treatment-naïve and experienced patients [39, 40], failed to use a confirmatory eGFR measurement [41, 42], or did not perform multivariable analyses [43]. Generally, results from our study were consistent with findings from other observational HIV
cohorts. In a follow-up of HIV patients enrolled in the Strategies for Management of Antiretroviral Therapy trial, co-infected patients were 72% more likely to develop CKD and end-stage renal disease (ESRD), relative to HIV mono-infected patients [44]. This study also found that hepatitis B virus co-infection was also strongly associated with CKD and ESRD, which we did not observe in our analysis (data not shown). An analysis of data from EuroSIDA, which had a similar CKD incidence rate (15 per 1000 PYFU) as observed in CANOC, also demonstrated a two-fold increase in the risk of eGFR-based CKD for HCV co-infected patients, although there was no evidence of a dose-response relationship with increasing HCV viral load [40]. In the Women’s Interagency HIV Study, HCV co-infection was associated with a decline in eGFR among women with existing CKD, suggesting our findings are not restricted to males who make up the majority of participants in observational HIV cohorts [39].

In our analyses, we identified several additional CKD risk factors such female sex, increasing age, lower eGFR at treatment initiation, increasing HIV viral load, and cumulative exposure to tenofovir and lopinavir, which have previously been identified [45, 46]. Unlike other settings in North America, however, we did not find an association between African/Caribbean ethnicity and incident CKD [47, 48]. African/Caribbean patients in CANOC were less likely to be co-infected and started cART at a younger age (median 37 years vs. 40 years), compared to non-African/Caribbean individuals. It is likely that this reduced risk in CKD among African/Caribbean individuals observed in this study can be attributed to the use of cART which substantially reduces the risk of HIVAN, a common consequence of untreated HIV infection in this population [49].

### Table 3

| Risk Factor            | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | Adjusted HR\(^d\) (95% CI) |
|-----------------------|------------------------|----------------------|-----------------------------|
| HIV viral load, per log\(_{10}\) copies/mL increase | 1.18 (1.01, 1.38)   | 1.20 (1.01, 1.43)   | 1.20 (1.01, 1.42)         |
| Year of cART initiation, per calendar year increase | 1.09 (0.99, 1.15)   | 1.07 (0.99, 1.15)   | 1.07 (0.99, 1.15)          |
| Tenofovir use, per cumulative year of use | 1.11 (0.99, 1.24)   | 1.12 (1.00, 1.25)   |                           |
| Atazanavir use, per cumulative year of use | 1.09 (0.98, 1.21)   | 1.10 (0.99, 1.23)   |                           |
| Lopinavir use, per cumulative year of use | 1.12 (1.02, 1.22)   | 1.12 (1.02, 1.23)   |                           |
| Liver fibrosis (APRI ≥1.5) | 1.50 (0.98, 2.30)   | 1.50 (0.98, 2.30)   |                           |
| Hypertension         | 1.69 (0.96, 2.99)    | N/A                  | 1.70 (0.91, 3.17)          |
| Diabetes             | 3.42 (2.29, 5.10)    | N/A                  | 1.47 (0.96, 2.26)          |

\(^{a}\) Multiple imputation used for missing data

\(^{b}\) Age and baseline eGFR were modeled with a linear spline

\(^{c}\) Hypertension and diabetes excluded from the model

\(^{d}\) Hypertension and diabetes included in the model

**Fig. 2** Cumulative incidence of chronic kidney disease by hepatitis C co-infection
There are several possible mechanisms by which HCV increases the risk of CKD. Declines in renal function could be brought about by HCV-induced glomerular diseases, namely membranoproliferative glomerulonephritis, which is driven by deposition of mixed immune complexes in the glomerular units of the kidney [8]. Indeed, a biopsy study of 249 HIV patients with CKD found that co-infected patients were twice as likely to have histopathologic evidence of immune-complex glomerulonephritides, compared to HIV mono-infected patients [50]. Alternatively, HCV co-infection may be associated with CKD by increasing the prevalence of traditional CKD risk factors. In HIV-infected populations, co-infection has been associated with insulin resistance [51] and increases in carotid intima-media thickness and atherosclerosis [52], early markers for diabetes and cardiovascular disease, respectively. Lastly, as with HIV, there is evidence that persistent HCV replication can result in systematic inflammation and immune activation leading to endothelial dysfunction, which is prevalent in patients with severe renal failure [53, 54].

As with previous research, we were unable to account for the possible role that current IDU practices may have on CKD. Active IDU is prevalent among co-infected individuals and has been associated with increases in serum creatinine concentration [55]. Previous research in co-infected populations have demonstrated that frequent use of injection cocaine, a known nephrotoxic stimulant, may explain part of the association between chronic HCV and CKD observed in previous studies [56]. In our analysis, IDU as a HIV risk factor was strongly collinear with HCV co-infection and therefore not included in multivariable analyses. Furthermore, past IDU is often a poor proxy and imperfect measure for current IDU behaviour. In the Canadian Co-Infection Cohort, for example, 81% of participants have an IDU risk factor, but only 34% remained active users [25]. We found no evidence, however, that the role of HCV co-infection differed between those with and without a past IDU risk factor, as has been suggested for HIV treatment outcomes, such as virologic suppression, CD4+ recovery and all-cause mortality [31]. Co-infected patients may also experience higher levels of additional CKD risk factors, such as NSAID use, smoking, alcohol abuse, and food insecurity, compared to HIV mono-infected patients. These variables were not available in CANOC and thus we cannot ascertain how much they contribute to our observed association.

If HCV co-infection is an important driver of CKD in HIV-infected patients in the modern cART era, then CKD is an extrahepatic complication that can potentially be impacted with wider uptake of HCV treatment with new direct acting antivirals. Indeed, a recent study found that HCV-HIV co-infected responders who were successfully treated with pegylated-interferon and ribavirin had a 60% reduction in the risk of renal events, compared to individuals who failed treatment [57]. These findings provide further evidence of a direct effect of ongoing HCV viral replication on CKD etiology in HIV-infected populations.

Our study has several limitations. First, we excluded a large proportion of patients who did not have a baseline serum creatinine measurement. These patients, who were more likely to be female, white and be HCV co-infected, were excluded because we could not determine if they had prevalent CKD at cART initiation. In a sensitivity analyses where included patients were weighted by their inverse-probability of being selected into the analysis, we found little evidence of selection bias as a result of our exclusion criteria. Second, the use of a single HCV antibody serology, without RNA testing confirmation, as part of the HCV exposure definition may result in misclassification, as approximately 20% of individuals will spontaneously clear their HCV infection within a year of exposure and will no longer be viremic. This misclassification is likely non-differential with respect to time to incident CKD and biases our findings towards the null. Third, CANOC patients exposed to HCV may have subsequently initiated treatment and could have developed a sustained virologic response. We expect this misclassification of person-time to be small as both the uptake of HCV treatment and SVR rates among HIV co-infected patients in the pre direct-acting antiviral era are low [25]. Fourth, given the asymptomatic nature of chronic HCV infection, we assumed HCV infection was present at baseline and subjects did not seroconvert after starting cART even if their first positive test or diagnosis occurred after treatment initiation. This assumption may not be valid if subjects engaged in high-risk behavior after starting cART, however previous studies have shown that HCV infection is often acquired prior to starting treatment and seroconversion is relatively rare when on stable cART [25, 58]. Fifth, we had no information regarding quantitative HCV viral load to further evaluate the association between viral replication and CKD, as has been suggested earlier [44]. This has limited our ability to assess the plausibility of HCV as an etiologic CKD risk factor. Finally, we did not have data on proteinuria measurements preventing the use of more rigorous CKD staging definitions [59].

Conclusions
The risk of CKD was more than two-fold greater in HCV co-infected compared to HIV mono-infected patients. Whether this risk is a solely a direct effect of HCV viral replication or is in part related to other associated risk factors, such as IDU, remains to be determined. Regardless, HCV-HIV co-infected individuals should be regularly
screened for CKD to identify those who may require modifications to potentially nephrotoxic HIV treatments and those who may benefit from interventions to reduce further decline in kidney function such as HCV treatment with new direct-acting antiviral therapy.

Additional file

Additional file 1: Supplemental content (Tables S1 to S4). (PDF 187 kb)

Abbreviations
AIDS: Acquired immune deficiency syndrome; APRI: Aspartate aminotransferase to platelet ratio index; CANOC: Canadian Observational Cohort; cART: Combination antiretroviral therapy; CI: Confidence interval; CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate; ESRD: End-stage renal disease; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; HIVAN: HIV-associated nephropathy; HR: Hazard ratio; IDU: Injection drug use; IQR: Interquartile range; MI: Multiple imputation; NSAID: Nonsteroidal anti-inflammatory drug; PH: Proportional hazards; PTVU: Person-years of follow-up; SC: Serum creatinine

Acknowledgements

We would like to thank all of the participants for allowing their information to be a part of the CANOC collaboration and Karyn Gabler and Chantal Burelle for their help with the submission process. The data was presented in part previously as a poster presentation at the 25th Annual Canadian Conference on HIV/AIDS Research in Winnipeg, Manitoba, on May 13th, 2016.

Funding

CANOC is funded by the Canadian Institutes of Health Research (CIHR) through a Centres Grant (Centres for HIV/AIDS Population Health and Health Services Research [CIHR #22684]), two Operating Grants (HIV/AIDS Priority Announcement [CIHR #134047], a Population and Public Health Grant [CIHR #13688]), a Foundation Grant (Expansion of Antiretroviral Therapy and its Impact on Vulnerable Populations in Canada and Global Settings [CIHR #143342]), and in collaboration with the CIHR Canadian HIV Trials Network (CTN #242). CR was supported by doctoral research award from the Canadian Institutes of Health Research. JR is supported by an Ontario HIV Treatment Network (OHTN, University of Toronto, ICES), Renee Masching (Canadian Aboriginal Council), Jerry Lawless (University of Waterloo), Douglas Lee (University Health Network, University of Toronto, ICES), and in-kind support from Gilead Sciences and Merck. SW has sat on advisory boards and has spoken at events for ViiV Healthcare, Gilead Sciences, Merck and Janssen. CC has received research grants, sat on advisory boards and has spoken at events for Gilead Sciences, Merck and Abbvie. MH has participated in advisory boards or speaking engagements for Abbvie, BMS, Gilead, Janssen, and Merck. All honoraria have been paid to his institution. MBK has participated in investigator-initiated trials from Merck and ViiV Healthcare; consulting fees from: ViiV Healthcare, Bristol-Meyers Squibb, Merck, Gilead and Abbvie. CR, TA, AB, JC, RSH, and EEMM have no conflicts to declare.

Competing interests

JR is a co-investigator on two projects outside the submitted work with in-kind support from Gilead Sciences and Merck. SW has sat on advisory boards and has spoken at events for ViiV Healthcare, Gilead Sciences, Merck and Janssen. CC has received research grants, sat on advisory boards and has spoken at events for Gilead Sciences, Merck and Abbvie. MH has participated in advisory boards or speaking engagements for Abbvie, BMS, Gilead, Janssen, and Merck. All honoraria have been paid to his institution. MBK has participated in investigator-initiated trials from Merck and ViiV Healthcare; consulting fees from: ViiV Healthcare, Bristol-Meyers Squibb, Merck, Gilead and Abbvie. CR, TA, AB, JC, RSH, and EEMM have no conflicts to declare. Consent for publications
Not applicable.
Ethics approval and consent to participate
The human subjects activities of CANOC were approved by the Simon Fraser University Research Ethics Board, the University of British Columbia Research Ethics Board and the following local institutional review boards of the participating cohorts: Providence Health Care Research Institute Office of Research Services, The Ottawa Hospital Research Ethics Board, University Health Network (UHN) Research Ethics Board, Véritas Institutional Review Board (IRB), Biomedical C. (BMC) Research Ethics Board of the McGill University Health Centre (MUHC), University of Toronto HIV Research Ethics Board (HIV REB), and Women's College Hospital Research Ethics Board. Local cohort studies have obtained written consent except for the following: HAART Observational Medical Evaluation and Research (IRB approves the retrospective use of anonymous administrative data without requiring consent; an information sheet for participants is provided in lieu of a consent form); Ottawa Hospital Ethical Review Board (IRB approves the anonymous use of data retrospectively abstracted from clinical care databases without requiring consent); UHN (REB approves the anonymous use of data retrospectively abstracted from clinical care databases without requiring consent); MUHC (IRB approves the anonymous use of data retrospectively abstracted from clinical care databases without requiring consent); and Effective Anti-Retroviral Therapy cohort (REB approves the anonymous use of data retrospectively abstracted from clinical care databases without requiring consent; patients sign a general waiver on opening a medical chart at the hospital but no specific study related consent). Maples Leafs Equipment (REB has approved the anonymous use of data retrospectively abstracted from clinical care databases without requiring consent; and Effective Anti-Retroviral Therapy cohort (REB approves the anonymous use of data retrospectively abstracted from clinical care databases without requiring consent; patients sign a general waiver on opening a medical chart at the hospital but no specific study related consent).

Author details
1Research Institute of the McGill University Health Centre, Montréal, Canada. 2Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. 3St. Michael's Hospital, University of Toronto, Toronto, Canada. 4BC Centre for Excellence in HIV/AIDS, Vancouver, Canada. 5Faculty of Medicine, University of British Columbia, Vancouver, Canada. 6Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada. 7Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Canada. 8Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, 1001 Decarie Boulevard, D02.4110, Montréal H4A 3J1, Canada.

Received: 13 December 2016 Accepted: 28 March 2017
Published online: 04 April 2017

References
1. Lima VO, Loueno-L, Yip B, Hogg RS, Phillips P, Montaner JS. AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV. 2015;2: e92–7.
2. Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, et al. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis. 2015;15:274.
3. Nsanzimana S, Remera E, Kanters S, Chan K, Forrest JI, Ford N, et al. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Glob Health. 2015;3:e169–77.
4. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS-related morbidity. BMJ. 2006;333:372.
5. Peters L, Klein MB. Epidemiology of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS. 2015;10:297–302.
6. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–77.
7. Negro F, Fenton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345–60.
8. Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS. 2015;10:309–15.
9. Tong X, Spradling PR. Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011. J Viral Hepat. 2015;22:906–13.
10. Crowell TA, Berry SA, Fleishman JA, LaRue RW, Korthuis PT, Nibhammad AE, et al. Impact of hepatitis confection on healthcare utilization among persons living with HIV. J Acquir Immune Defic Syndr. 2015;68:425–31.
11. Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV. 2014 update by the HIV Medicine Association of the Infective Diseases Society of America. Clin Infect Dis. 2014;59:e96–138.
12. Chai Ai, Li Y, Deeks SG, Grünfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121:651–8.
13. Mocroft A, Ryom L, Bergovac J, Monforte A, Vasilienko A, Gatlj J, et al. Deteriorating renal function and clinical outcomes in HIV-positive persons. AIDS. 2014;28:277–37.
14. Ryom L, Lundgren JD, Ross M, Kirk O, Law M, Morlat P, et al. Renal impairment and cardiovascular disease in HIV-positive individuals: the D:A:D study. J Infect Dis. 2016;214:1212–20.
15. Roling J, Schmid H, Fischlereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis. 2006;42:1488–95.
16. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlak O, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667–78.
17. Ryom L, Mocroft A, Lundgren JD. Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons. Curr Opin HIV AIDS. 2014;9:41–7.
18. Johnson RJ, Gretch DR, Yambane H, Hart J, Jacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993;329:465–70.
19. Pipili C, Iliopoulou C, Cholongitas E. Hepatitis C virus and kidney: a strong association with different clinical aspects. Liver Int. 2011;31:1071–80.
20. Miyajima I, Kawaguchi T, Fukami A, Nagao Y, Adachi H, Sasaki S, et al. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. J Gastroenterol. 2013;48:93–100.
21. Wyatt CM, Malvestutto C, Coca SG, Klotman PE, Parikh CR. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS. 2008;22:1799–807.
22. Palmer AK, Klein MB, Raboud J, Cooper C, Hosein S, Loutfy M, et al. Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol. 2011;40:25–32.
23. Levey AS, Stevens LA, Shchipoch C, Zhang YL, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
24. Inker LA, Wyatt C, Creamer R, Hellinger J, Hotta M, Leppo M, et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr. 2012;61:302–9.
25. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
26. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
27. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
28. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
29. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
30. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
31. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
32. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
33. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
coinfected individuals with and without injection drug use history. AIDS. 2014;28:121–7.
32. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377–99.
33. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28:1992–98.
34. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22:278–95.
35. Gillis J, Cooper C, Burchell AN, Gardner S, Manno M, Mazzulli T, et al. Time-dependent bias in hepatitis C classification. Epidemiology. 2015;26:e24–6.
36. Carpenter JR, Kenward MG. Multiple imputation and its application. West Sussex: Wiley; 2013.
37. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–85.
38. Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr. 2016;71:530–7.
39. Tsui J, Vittinghoff E, Anastos K, Augenbraun M, Young M, Nowicki M, et al. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. Am J Kidney Dis. 2009;54:43–50.
40. Peters L, Grint D, Lundgren JD, Rockstroh JK, Soni V, Reiss P, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012;26:1917–26.
41. Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I, Cohen AJ, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007;21:2101–3.
42. Achhra AC, Mocroft A, Ross MJ, Ryom L, Lucas GM, Furrer H, et al. Kidney disease in antiretroviral-naive HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(Suppl 1):55–63.
43. Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Deti E, et al. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One. 2012;7:e40245.
44. Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, et al. Hepatitis C and covariates are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One. 2012;7:e40246.
45. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3:e23–32.
46. Abraham AG, Althoff KN, Jing Y, Estrella MM, Kitahata MM, Wester CW, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015;60:941–9.
47. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis. 2008;197:1548–57.
48. Rollet K, Munro H, Haberlen SA, Post WS, Brown TT, Budoff M, Witt MD, et al. Hepatitis C virus seroconversion among HIV-positive men who have sex with men with no history of injection drug use: results from a clinical HIV cohort. Can J Infect Dis Med Microbiol. 2015;26:17–22.
49. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–75.